← Leaderboards
Sean S Park
Mayo Clinic Rochester
$1,787,171
Attributed
$4,810,222
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,810,222 · 4
By mechanism
R01$4,446,940 · 3
R21$363,282 · 1
Top collaborators
- Yi Lin6 shared
- Lewis R Roberts6 shared
- Haidong Dong3 shared
- Jacob Orme2 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Wenqian Hu$5,205,101
- Yi Lin$6,996,175
- Ian J Welsby$1,582,196
- Richard G Vile$15,977,609
- Daryl J Kor$1,975,293
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorSignal TransductionCellsBloodImmunotherapyRadiation TherapyT-LymphocyteImmuneImmune Checkpoint InhibitorCd8-Positive T-LymphocytesProgrammed Cell Death Protein 1Operative Surgical ProceduresPhase Ii Clinical TrialsProgrammed Cell Death Ligand 1Novel TherapeuticsPartial ResponseProgression-Free SurvivalsMediatingInflammatoryNeoantigensInvestigationInsightNeoplastic CellCytotoxic
Grant awards (11)
Radiation and dendritic cells to hepatomas to improve immunotherapy response$628,467
R01 · FY2025 · CA · contact PI
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma$610,890
R01 · FY2025 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$612,951
R01 · FY2024 · CA · contact PI
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma$610,890
R01 · FY2024 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$612,054
R01 · FY2023 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$632,389
R01 · FY2022 · CA · contact PI
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma$161,411
R21 · FY2022 · CA · contact PI
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma$201,871
R21 · FY2021 · CA · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$244,801
R01 · FY2018 · CA · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$247,249
R01 · FY2017 · CA · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$247,249
R01 · FY2016 · CA · contact PI